PA8495701A1 - Profarmacos mutuos de amlodipino y atorvastatina - Google Patents

Profarmacos mutuos de amlodipino y atorvastatina

Info

Publication number
PA8495701A1
PA8495701A1 PA20008495701A PA8495701A PA8495701A1 PA 8495701 A1 PA8495701 A1 PA 8495701A1 PA 20008495701 A PA20008495701 A PA 20008495701A PA 8495701 A PA8495701 A PA 8495701A PA 8495701 A1 PA8495701 A1 PA 8495701A1
Authority
PA
Panama
Prior art keywords
atorvastatine
amlodipine
mutual
drugs
propharmacs
Prior art date
Application number
PA20008495701A
Other languages
English (en)
Inventor
Ernest Seiichi Hamanaka
John Lawrence Lamattina
George Chang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8495701A1 publication Critical patent/PA8495701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE A PROFÁRMACOS MUTUOS DE AMLODIPINO Y ATORVASTATINA Y A LAS COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS. ESTA INVENCIÓN TAMBIÉN SE REFIERE A LOS PROCEDIMIENTOS PARA TRATAR LA ANGINA DE PECHO, LA ATEROSCLEROSIS Y LA HIPERTENSION Y LA HIPERLIPIDEMIA EN UN MAMÍFERO MEDIANTE EL USO DE ESTOS PROFÁRMACOS Y COMPOSICIONES. ESTA INVENCIÒN TAMBIÉN SE REFIERE A LOS PROCEDIMIENTOS PARA TRATAR EL RIESGO CARDÍACO EN UN MAMÍFERO, INCLUYENDO HUMANOS, QUE PRESENTA SÌNTOMAS DE RIESGO CARDÍACO MEDIANTE LA ADMINISTRACIÒN DE ESTOS PROFÁRMACOS Y COMPOSICIONES.
PA20008495701A 1999-05-27 2000-05-19 Profarmacos mutuos de amlodipino y atorvastatina PA8495701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
PA8495701A1 true PA8495701A1 (es) 2001-12-14

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008495701A PA8495701A1 (es) 1999-05-27 2000-05-19 Profarmacos mutuos de amlodipino y atorvastatina

Country Status (41)

Country Link
US (1) US6486182B1 (es)
EP (1) EP1180102B9 (es)
JP (1) JP2003500487A (es)
KR (1) KR20020012247A (es)
CN (1) CN1352640A (es)
AP (1) AP2001002345A0 (es)
AR (1) AR022344A1 (es)
AT (1) ATE268764T1 (es)
AU (1) AU3313900A (es)
BG (1) BG106149A (es)
BR (1) BR0011006A (es)
CA (1) CA2375372C (es)
CO (1) CO5170457A1 (es)
CZ (1) CZ20014229A3 (es)
DE (1) DE60011424T2 (es)
DK (1) DK1180102T3 (es)
DZ (1) DZ3048A1 (es)
EA (1) EA200101130A1 (es)
EE (1) EE200100631A (es)
ES (1) ES2220426T3 (es)
GT (1) GT200000078A (es)
HK (1) HK1046282A1 (es)
HN (1) HN2000000075A (es)
HR (1) HRP20010856A2 (es)
HU (1) HUP0201433A2 (es)
IL (1) IL145947A0 (es)
IS (1) IS6135A (es)
MA (1) MA26736A1 (es)
MX (1) MXPA01012125A (es)
NO (1) NO20015756L (es)
OA (1) OA11950A (es)
PA (1) PA8495701A1 (es)
PE (1) PE20010169A1 (es)
PL (1) PL353483A1 (es)
PT (1) PT1180102E (es)
SK (1) SK16792001A3 (es)
SV (1) SV2002000082A (es)
TN (1) TNSN00113A1 (es)
TR (1) TR200103391T2 (es)
WO (1) WO2000073298A1 (es)
ZA (1) ZA200109691B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
HUP0400167A3 (en) * 2001-06-11 2012-09-28 Xenoport Inc Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
EP1909848A2 (en) * 2005-08-01 2008-04-16 PSivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8371336B2 (en) 2007-10-10 2013-02-12 Eagle Industry Co., Ltd. Accumulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
DK1180102T3 (da) 2004-09-06
PT1180102E (pt) 2004-08-31
WO2000073298A1 (en) 2000-12-07
IS6135A (is) 2001-10-30
ZA200109691B (en) 2002-11-26
AU3313900A (en) 2000-12-18
AP2001002345A0 (en) 2001-12-31
DE60011424T2 (de) 2005-08-25
CZ20014229A3 (cs) 2003-01-15
AR022344A1 (es) 2002-09-04
PE20010169A1 (es) 2001-02-10
NO20015756L (no) 2002-01-24
CA2375372C (en) 2007-01-09
TR200103391T2 (tr) 2002-04-22
JP2003500487A (ja) 2003-01-07
ATE268764T1 (de) 2004-06-15
NO20015756D0 (no) 2001-11-26
BR0011006A (pt) 2002-02-19
DZ3048A1 (fr) 2004-03-27
MA26736A1 (fr) 2004-12-20
EP1180102B9 (en) 2005-03-02
HK1046282A1 (zh) 2003-01-03
HRP20010856A2 (en) 2002-12-31
EP1180102B1 (en) 2004-06-09
KR20020012247A (ko) 2002-02-15
HN2000000075A (es) 2001-02-02
CN1352640A (zh) 2002-06-05
IL145947A0 (en) 2002-07-25
TNSN00113A1 (fr) 2005-11-10
SK16792001A3 (sk) 2003-03-04
MXPA01012125A (es) 2002-06-04
SV2002000082A (es) 2002-02-05
BG106149A (en) 2002-05-31
ES2220426T3 (es) 2004-12-16
EP1180102A1 (en) 2002-02-20
HUP0201433A2 (en) 2002-08-28
PL353483A1 (en) 2003-11-17
EA200101130A1 (ru) 2002-04-25
CO5170457A1 (es) 2002-06-27
DE60011424D1 (de) 2004-07-15
OA11950A (en) 2006-04-13
EE200100631A (et) 2003-02-17
CA2375372A1 (en) 2000-12-07
GT200000078A (es) 2001-11-16
US6486182B1 (en) 2002-11-26

Similar Documents

Publication Publication Date Title
PA8495701A1 (es) Profarmacos mutuos de amlodipino y atorvastatina
UY26163A1 (es) Sal mutua de amlodipino y atorvastatina
AR012269A1 (es) COMPOSICIoN FARMACÉUTICA Y USO DE LA MISMA PARA LA FABRICACIoN DE MEDICAMENTOS
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
UY27402A1 (es) Composiciones farmacéuticas de amlodipina y atorvastatina
CO4970724A1 (es) Terapia de combinacion
ES2175127T3 (es) Derivados de la quinazolina y su uso.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
UY26817A1 (es) Agentes antiinflamatorios selectivos de glucocorticoides
GT199800134A (es) Terapia de combinacion.
AR022970A1 (es) Compuestos antagonistas de la lhrh con propiedades mejoradas de sulubilidad, procedimiento para prepararlos, las composiciones farmrceuticas que los contienen, su uso para la preparacinn de medicamentos, y procedimiento para preparar dichos medicamentos
UY26164A1 (es) Profarmácos mutuos de amlodipino y atorvastatina
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
DOP2001000150A (es) Agente hipertensivo y su uso
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina
ES2188797T3 (es) Sales de n-(4-oxo-2-(1h-tetrazoil-5-il)-4h-1 benzopran-8-il)-4-(4-fenilbutoxi)benzamida.
ECSP003609A (es) Derivados de 2- dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
ECSP003598A (es) Derivados de 1,5- dihidropirrol-2-ona sustituida, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
ECSP982646A (es) Combinaciones terapeuticas
ECSP982647A (es) Terapia de combinacion
UY27406A1 (es) Derivados de 2h-1-benzopirano, procesos para su preparación y composiciones farmacéuticas que los contienen
AR013115A1 (es) COMPUESTOS DE 2,6-DI-t-BUTIL-4-[(DIMETIL-METOXIFENILSILIL)METIL-OXI]FENOL UTILES EN LA INHIBICION DE LA ARTERIOESCLEROSIS, COMPOSICIONES FARMACEUTICASY USOS EN LA FABRICACION DE MEDICAMENTOS QUE INCLUYEN DICHOS COMPUESTOS